180 related articles for article (PubMed ID: 25160476)
21. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver.
Lin T; Chen H; Koustova E; Sailhamer EA; Li Y; Shults C; Liu B; Rhee P; Kirkpatrick J; Alam HB
Surgery; 2007 Jun; 141(6):784-94. PubMed ID: 17560255
[TBL] [Abstract][Full Text] [Related]
22. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
23. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
Faraco G; Pancani T; Formentini L; Mascagni P; Fossati G; Leoni F; Moroni F; Chiarugi A
Mol Pharmacol; 2006 Dec; 70(6):1876-84. PubMed ID: 16946032
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis for histone acetylation of human colon cancer cells treated with a novel HDAC inhibitor.
Zhao Y; Fang X; Wang Y; Zhang J; Jiang S; Liu Z; Ma Z; Xu L; Li E; Zhang K
Curr Pharm Des; 2014; 20(11):1866-73. PubMed ID: 23888955
[TBL] [Abstract][Full Text] [Related]
26. RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.
Zhan Q; Tsai S; Lu Y; Wang C; Kwan Y; Ngai S
PLoS One; 2013; 8(8):e71663. PubMed ID: 23977108
[TBL] [Abstract][Full Text] [Related]
27. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
28. Prenatal exposure to suberoylanilide hydroxamic acid perturbs corticogenesis.
Yuniarti N; Juliandi B; MuhChyi C; Noguchi H; Sanosaka T; Nakashima K
Neurosci Res; 2013; 77(1-2):42-9. PubMed ID: 23831515
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
Ge Y; Gong Z; Olson JR; Xu P; Buck MJ; Ren X
Toxicology; 2013 Oct; 312():30-5. PubMed ID: 23891734
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
[TBL] [Abstract][Full Text] [Related]
32. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
33. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication.
Sato A; Saito Y; Sugiyama K; Sakasegawa N; Muramatsu T; Fukuda S; Yoneya M; Kimura M; Ebinuma H; Hibi T; Ikeda M; Kato N; Saito H
J Cell Biochem; 2013 Sep; 114(9):1987-96. PubMed ID: 23519646
[TBL] [Abstract][Full Text] [Related]
34. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
35. Trichostatin A epigenetically increases calpastatin expression and inhibits calpain activity and calcium-induced SH-SY5Y neuronal cell toxicity.
Seo J; Jo SA; Hwang S; Byun CJ; Lee HJ; Cho DH; Kim D; Koh YH; Jo I
FEBS J; 2013 Dec; 280(24):6691-701. PubMed ID: 24200051
[TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
37. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
38. SAHA and curcumin combinations co-enhance histone acetylation in human cancer cells but operate antagonistically in exerting cytotoxic effects.
Zhao JY; Lu N; Yan Z; Wang N
J Asian Nat Prod Res; 2010 May; 12(5):335-48. PubMed ID: 20496190
[TBL] [Abstract][Full Text] [Related]
39. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
[TBL] [Abstract][Full Text] [Related]
40. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]